Source - RNS
RNS Number : 0779L
ValiRx PLC
28 September 2016
 

 

 

VALIRX PLC

("ValiRx" or "the Company")

 

SHAREHOLDER CIRCULAR AND NOTICE OF GENERAL MEETING

 

London, UK, 28 September 2016: ValiRx Plc (AIM: VAL), a life science company which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, announces that it has recently published and posted to shareholders a circular and notice convening a General Meeting of ValiRx Plc to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 9:30 a.m. on 12th October 2016.

 

The directors will propose at the General Meeting shareholder resolutions seeking shareholder authority to allot shares and the dis-application of pre-emptive rights.

 

A copy of the Circular is available on the Company's website: www.valirx.com

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx Plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

[email protected]

Mark Treharne, Corporate Development Manager

Tel: +44 (0) 7736 564 686

[email protected]



Cairn Financial Advisers LLP (Nominated Adviser)

Tel: +44 (0) 20 7148 7900

Liam Murray / Jo Turner




Northland Capital Partners Limited (Joint Broker)

Tel: +44 (0) 203 861 6625

Patrick Claridge / David Hignell (Corporate Finance)

John Howes / Abigail Wayne (Broking)




Beaufort Securities Limited (Joint Broker)

Tel: +44 (0) 207 382 8300

Jon Belliss


 

Notes for Editors

 

ValiRx Plc

ValiRx is a biotechnology oncology focussed company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's three classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOGAKFDKKBKDFCB

Related Charts

ValiRx (VAL)

-0.50p (-7.41%)
delayed 18:15PM